MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Lymphoma Diagnosis and Treatment
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

3,251 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
3,251 works in the cohort · of 4,299,418page 34 of 66

Labels cover 5 of 3,251 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 3,251 of 3,251 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Treatment with 6 Cycles of CVP or R-CVP after Involved Field Radiation Therapy (IFRT) Significantly Improves Progression-free Survival Compared to IFRT alone in Stage I-II Low Grade Follicular Lymphoma: Results of an International Randomized Trial
Michael MacManus, Richard Fisher, Daniel Roos, Peter C. O’Brien, Andrew Macann, David Christie +5 more
2016· article· en· International Journal of Radiation Oncology*Biology*Physics· Medicine
machine prediction:candidate · noneconsensus · none
5
citations
afffundno abstractunlabeled
Molecular biomarkers in classic Hodgkin lymphoma
Makoto Kishida, Manabu Fujisawa, Christian Steidl
2024· review· en· Seminars in Hematology· Medicine
machine prediction:candidate · noneconsensus · none
5
citations
affunlabeled
Transformed Lymphoma: Incidence and Long-Term Outcome.
Abdulwahab J. Al-Tourah, Mukesh Chhanabhai, Paul Hoskins, Richard Klasa, Kerry J. Savage, L. H. Sehn +3 more
2004· article· en· Blood· Medicine
machine prediction:candidate · noneconsensus · none
5
citations
affunlabeled
Efficacy and Safety of Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in a Subset of Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients (Pts) Medically Eligible for Transplantation in the Randomized Phase 3 LYM-3002 Study (NCT00722137)
Johannes Drach, Huiqiang Huang, Olga Samoilova, Andrew R. Belch, Charles M. Farber, André Bosly +11 more
2014· article· en· Blood· Medicine
machine prediction:candidate · noneconsensus · none
5
citations

How this was built: Screen · Findings · About